Comparison of two ayurvedic medicine in the patients suffering from skin disease

COMPARATIVE PHASE II CLINICAL STUDY TO EVALUATE EFFICACY OF TABLET RUBYCLIN AND TABLET TAKZEMA IN THE MANAGEMENT OF VICHARCHIKA. WITH SPECIAL REFERENCE TO ECZEMA

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/10/021747

Enrollment

Registered

2019-10-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L20-L30- Dermatitis and eczema

Interventions

Intervention1: Tab Rubyclin: Two tablets each weighing 600 mg twice daily after meal with water for 30 days Control Intervention1: Tab Takzema: Two tablets each weighing 645 mg twice daily after meal

Eligibility

Inclusion criteria

Inclusion criteria: Patients with clinical features of Vicharchika having signs and symptoms namely Kandu (itching),Pidaka(Eruption),Vaivarnya(Depigmentation) and Srava (Discharge). Understanding and being willing to sign the informed concent form.

Exclusion criteria

Exclusion criteria: Patient having severe systemic diseases or condition along with Vicharchika. Pregnant & Lactating woman.

Design outcomes

Primary

Measure	Time frame
Reduction In Signs And Symptoms Of Eczema.Timepoint: 30 Days	—

Secondary

Measure	Time frame
Change In EASI SCALE . Timepoint: 30 days	—

Countries

India

Contacts

Public ContactDr Babasaheb Rangrao Deshmukh

Ayurved seva sangh Ayurved College Nashik

ekulkarni6@gmail.com9850071240

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026